Medicine Press release

Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on time savings with continued treatment with humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name, U.S. brand name LEQEMBI(R)) were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on time savings with continued treatment with humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name, U.S. brand name LEQEMBI(R)) were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the latest data confirming the pharmacological effect of lecanemab, an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the latest data confirming the pharmacological effect of lecanemab, an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the latest data confirming the pharmacological effect of lecanemab, an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference.
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at the 18th Clinical Trials on Alzheimer's Disease Conference (CTAD).
More info..

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at the 18th Clinical Trials on Alzheimer's Disease Conference (CTAD).
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has filed a new drug application for "LEQEMBI(R)" (brand name, generic name: lecanemab) seeking approval for a subcutaneous formulation (subcutaneous autoinjector: SC-AI) as a new route of administration to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has filed a new drug application for "LEQEMBI(R)" (brand name, generic name: lecanemab) seeking approval for a subcutaneous formulation (subcutaneous autoinjector: SC-AI) as a new route of administration to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
More info..

The Japanese Foundation for Cancer Research (JFCR), NEC Corporation (NEC), and Taiho Pharmaceutical Co., Ltd. (Taiho) have signed a three-party joint research (Joint Research) agreement aimed at developing new cancer vaccines through the utilization of whole-genome information.
More info..